On August 26, 2020 Oncopeptides reported interim result Q2 2020 (Press release, Oncopeptides, AUG 26, 2020, View Source [SID1234564028])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Financial overview April 1 – June 30, 2020
Net sales amounted to SEK 0.0 M (0.0)
Loss for the period was SEK 401.0 M (loss: 171.9)
Loss per share, before and after dilution, was SEK 6.79 (loss: 3.52)
On June 30 cash and cash equivalents amounted to SEK 937.8 M (626.8)
Significant events during the period April 1 – June 30, 2020
Marty J Duvall was appointed CEO from July 1, and Jakob Lindberg assumed the role as
Chief Scientific Officer
NDA for accelerated approval of melflufen in the U.S was submitted
A laboratory for preclinical development was taken over to strengthen the technology platform and build the company’s pipeline
A directed share issue of SEK 1,414 M (USD 144 M) (before issue costs) to well-known life science investors, out of which SEK 716.4 M (before issue costs) was paid in after the end of the reporting period was completed
Enrollment in the OCEAN phase 3 study continues after the initial recruitment goal of 450 patients was reached in May
Final data from the pivotal HORIZON study were presented at EHA (Free EHA Whitepaper)
Patient enrollment to the company’s exploratory clinical studies was resumed in May after a temporary pause due to the COVID-19 pandemic
Significant events after the reporting period
The first patient was enrolled in the phase 1/2 AL-Amyloidosis study. This is the first study with melflufen in an indication outside multiple myeloma
Oncopeptides started a phase 2 study called PORT to evaluate an alternative administration of melflufen
Financial overview of the group

Conference call for investors, analysts and the media
The Interim Report Q2 2020 and an operational update will be presented by CEO Marty J Duvall and members of Oncopeptides management team, Wednesday August 26, 2020 at 14:00 (CET). The conference call will also be streamed via a link on the website: www. oncopeptides.com.

Financial calendar
Interim Report Q3, 2020: November 19, 2020
Year-end Report 2020: February 18, 2021
Interim Report Q1 2021: May 26, 2021
Annual General Meeting 2021: May 26, 2021

This information is information that Oncopeptides is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 08:00 CET on August 26, 2020.